Evidence map›Paper›PMID 40338302›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2025

HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.

Yuan Gao, Lei Yin, Xiaojiang Duan, Zijian Fu, Qian Liu, Jinzhi Chen, Ling Xin, Xiaojuan Zhu, Hongyu Xiang, Ling Xu and 2 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06289517 (A Study to Evaluate 68Ga-Her2-affibody PET/CT Imaging of Her2 Expression in Tumors), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06289517 narecruitingnot on this map

A Study to Evaluate 68Ga-Her2-affibody PET/CT Imaging of Her2 Expression in Tumors

TypeinterventionalSponsorPeking University First HospitalRan2024 to 2025Enrolled30ConditionsNeoplasmsArms68Ga-Her2-affibody
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Anti-HER2 nanobody 5F7-based theranostics using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuan Gao *Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Lei Yin *Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Zijian FuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Qian LiuThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Jinzhi ChenDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Ling XinThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Xiaojuan ZhuDepartment of Pathology, Peking University First Hospital, Beijing, China.
Hongyu XiangThyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Ling XuThyroid and Breast Surgery, Peking University First Hospital, Beijing, China. Ling.xu@pkufh.com.ORCID 0000-0002-9236-3014
Jingming YeThyroid and Breast Surgery, Peking University First Hospital, Beijing, China. md_ye@sina.com.ORCID 0009-0007-5740-0602
Meng LiuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, China. louisa_liu@bjmu.edu.cn.ORCID 0000-0002-6960-3163

Funding

Beijing Natural Science Foundation Z210007National High-Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital) 2022CR34National Natural Science Foundation of China 82172052Youth Clinical Research Special Fund Project of Peking University First Hospital 2023YC26
6 · The paper itself

Abstract

purposeHuman epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with

methodsIn this prospective study conducted from May 2024 to Jan 2025, participants with newly diagnosed breast cancer underwent both

resultsA total of 57 female participants (58 primary lesions) with newly diagnosed breast cancer were included. In the paired comparison of

conclusionHER2-targeted PET/CT imaging demonstrated distinct advantages over CLINICALTRIALS: GOV IDENTIFIER: NCT06289517 (2024-03-04).

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPositron Emission Tomography Computed TomographyAdultAgedFemaleFluorodeoxyglucose F18Gallium RadioisotopesHumansMiddle AgedProspective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Gallium Radioisotopes18F-FDG PET/CTAntibody-drug conjugates (ADCs)Breast cancerHER2-affibodyHER2-low

Identifiers

PMID40338302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.